Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $76.00. The company’s shares closed yesterday at $60.79.
According to TipRanks, Suvannavejh is an analyst with an average return of -1.0% and a 44.76% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Athira Pharma, and Cerevel Therapeutics Holdings.
Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $87.44, representing a 43.84% upside. In a report released on September 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $210.00 price target.
See today’s best-performing stocks on TipRanks >>
AXSM market cap is currently $2.45B and has a P/E ratio of -15.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Eldorado Gold Signs Mandate Letter for Skouries Project Finance Facility
- Analysts Are Bullish on These Healthcare Stocks: Plus Therapeutics (PSTV), IVERIC bio (ISEE)
- Stock Market Today: Futures on Indexes Down as Investors Gauge Economic Situation
- Analysts Offer Insights on Healthcare Companies: Applied DNA Sciences (APDN), Synlogic (SYBX) and Immunocore Holdings (IMCR)
- H.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)
